- Conditions
- Breast Cancer, Healthy, no Evidence of Disease
- Interventions
- Random fine need aspiration (rFNA), Mammogram
- Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 879
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Suppression of Ovulation
- Interventions
- 10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day
- Drug
- Lead sponsor
- Kimberly Myer
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- drospirenone and ethinyl estradiol (YAZ), Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- estramustine phosphate sodium, paclitaxel
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 27
- States / cities
- Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 18 more
- Conditions
- Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 368
- States / cities
- Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
- Interventions
- RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
- Drug
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
- Conditions
- Prevention of Pregnancy
- Interventions
- Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 938 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 39
- States / cities
- Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Copanlisib, Fulvestrant
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Sacramento, California • Boston, Massachusetts • New York, New York + 4 more
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
- Interventions
- Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- Olema Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
- Conditions
- Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
- Interventions
- Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- HIV Infection, Menopause
- Interventions
- Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
- Conditions
- HIV/AIDS, Gender, Behavior and Behavior Mechanisms
- Interventions
- TDF/FTC
- Drug
- Lead sponsor
- Hektoen Institute for Medical Research
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
- Interventions
- NUV-422, Fulvestrant
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more
- Conditions
- Polycystic Ovary Syndrome, Hyperandrogenism
- Interventions
- Flutamide, Progesterone, estrace
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 13 Years to 17 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Prostate Cancer
- Interventions
- doxorubicin hydrochloride, estramustine phosphate sodium, drug resistance inhibition treatment
- Drug · Procedure
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2013
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Menopausal Syndrome
- Interventions
- Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Endometriosis
- Interventions
- 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
- Drug
- Lead sponsor
- Main Line Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, estramustine phosphate sodium, ketoconazole, therapeutic hydrocortisone
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 98
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 76 more
- Conditions
- Type 1 Diabetes
- Interventions
- Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
- Drug
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- HIV, Immune Cells (Mucosal and Systemic), Contraception
- Interventions
- levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion
- Drug · Device
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception
- Interventions
- Non-hormonal period, Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
- Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sleep Initiation and Maintenance Disorders, Depression
- Interventions
- Estrogen Replacement Therapy, Zolpidem, placebo
- Drug
- Lead sponsor
- Hadine Joffe, MD
- Other
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Uterine Fibroids (UF)
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Arlington, Virginia